JP2016518403A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518403A5
JP2016518403A5 JP2016512480A JP2016512480A JP2016518403A5 JP 2016518403 A5 JP2016518403 A5 JP 2016518403A5 JP 2016512480 A JP2016512480 A JP 2016512480A JP 2016512480 A JP2016512480 A JP 2016512480A JP 2016518403 A5 JP2016518403 A5 JP 2016518403A5
Authority
JP
Japan
Prior art keywords
trehalose
pharmaceutical
pharmaceutical formulation
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016512480A
Other languages
English (en)
Japanese (ja)
Other versions
JP6837835B2 (ja
JP2016518403A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2014/050411 external-priority patent/WO2014181333A2/en
Publication of JP2016518403A publication Critical patent/JP2016518403A/ja
Publication of JP2016518403A5 publication Critical patent/JP2016518403A5/ja
Application granted granted Critical
Publication of JP6837835B2 publication Critical patent/JP6837835B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016512480A 2013-05-07 2014-05-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 Active JP6837835B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07
US61/820,278 2013-05-07
PCT/IL2014/050411 WO2014181333A2 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019075517A Division JP2019142907A (ja) 2013-05-07 2019-04-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療

Publications (3)

Publication Number Publication Date
JP2016518403A JP2016518403A (ja) 2016-06-23
JP2016518403A5 true JP2016518403A5 (enExample) 2017-06-15
JP6837835B2 JP6837835B2 (ja) 2021-03-03

Family

ID=51022384

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016512480A Active JP6837835B2 (ja) 2013-05-07 2014-05-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2019075517A Pending JP2019142907A (ja) 2013-05-07 2019-04-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2021095562A Pending JP2021152032A (ja) 2013-05-07 2021-06-08 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2023002536A Pending JP2023040211A (ja) 2013-05-07 2023-01-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2025036306A Pending JP2025087858A (ja) 2013-05-07 2025-03-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019075517A Pending JP2019142907A (ja) 2013-05-07 2019-04-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2021095562A Pending JP2021152032A (ja) 2013-05-07 2021-06-08 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2023002536A Pending JP2023040211A (ja) 2013-05-07 2023-01-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2025036306A Pending JP2025087858A (ja) 2013-05-07 2025-03-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療

Country Status (14)

Country Link
US (4) US10493023B2 (enExample)
EP (2) EP2994145B1 (enExample)
JP (5) JP6837835B2 (enExample)
KR (1) KR20160009617A (enExample)
AU (5) AU2014264228A1 (enExample)
CA (2) CA3239805A1 (enExample)
CR (1) CR20150637A (enExample)
EA (1) EA201501054A1 (enExample)
IL (1) IL241757B (enExample)
MD (1) MD20150120A2 (enExample)
MX (1) MX2015015355A (enExample)
PE (1) PE20160012A1 (enExample)
SG (1) SG11201509030TA (enExample)
WO (1) WO2014181333A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084720B2 (en) * 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
US20220288096A1 (en) * 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
SG11201509030TA (en) 2013-05-07 2015-11-27 Bio Blast Pharma Ltd Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
WO2017136922A1 (en) * 2016-02-08 2017-08-17 Junaxo, Inc. Use of trehalose for treatment of neurological diseases
JP7302871B2 (ja) 2016-04-21 2023-07-04 ベイラー カレッジ オブ メディスン リソソーム蓄積障害およびリソソーム機能不全によって特徴付けられる障害を治療するための組成物および方法
BR112020003119A2 (pt) 2017-08-14 2020-10-13 Prilenia Neurotherapeutics Ltd. método de tratamento de esclerose lateral amiotrófica com pridopidina
US11844808B2 (en) 2018-01-16 2023-12-19 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
IL291799A (en) * 2019-10-01 2022-06-01 Seelos Therapeutics Inc Trehalose formulations and uses thereof
MX2022010006A (es) * 2020-02-13 2022-09-19 Prilenia Neurotherapeutics Ltd Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo.
WO2022013940A1 (ja) 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体
CN116966192A (zh) * 2022-09-26 2023-10-31 西安文理学院 海藻糖在制备sca3疾病治疗药物中的应用
AU2023403437A1 (en) * 2022-11-30 2025-06-19 GLD Debt Acquisition 2025-1, Inc. Trehalose for treating huntington's disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS4950521U (enExample) 1972-08-14 1974-05-02
JPS516109B2 (enExample) 1972-12-28 1976-02-25
JPS557829Y2 (enExample) 1974-07-01 1980-02-21
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
WO1997024129A1 (en) 1995-12-27 1997-07-10 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
AU781975B2 (en) 2000-09-14 2005-06-23 Hayashibara Co., Ltd Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) * 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
KR101217382B1 (ko) 2003-02-13 2012-12-31 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 α,α-트레할로오스의 당질 유도체를 함유하는 것을 특징으로 하는 피부 외용제
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) * 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
CA2608198A1 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
WO2007018124A1 (ja) 2005-08-11 2007-02-15 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo コラーゲン産生増強剤とその用途
JP5192804B2 (ja) 2005-11-30 2013-05-08 日清オイリオグループ株式会社 トレハロース脂肪酸エステル組成物
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
WO2007111214A1 (ja) 2006-03-27 2007-10-04 Otsuka Chemical Co., Ltd. トレハロース化合物および該化合物を含有する医薬
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
EP2123662B1 (en) 2007-01-31 2013-12-04 Glytech, Inc. Trehalose compound, process for production of the compound, and immuno-stimulative agent comprising the compound
EP2198869B1 (en) * 2007-02-23 2015-09-16 Next 21 K.K. Trehalose for the treatment or prevention of vasospasm
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US8206751B2 (en) * 2007-10-31 2012-06-26 Diffusion Pharmaceuticals Llc Class of therapeutics that enhance small molecule diffusion
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
WO2010008860A1 (en) * 2008-06-23 2010-01-21 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) * 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
WO2010050178A1 (ja) 2008-10-31 2010-05-06 大塚化学株式会社 トレハロース化合物、その製造方法、及び該化合物を含有する医薬
BRPI0921845A2 (pt) * 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
PT3112358T (pt) 2008-12-10 2020-06-23 Wista Lab Ltd Sais de xantílio 3,6-dissubstituídos
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP5869882B2 (ja) 2010-03-05 2016-02-24 株式会社林原 インスリン抵抗性の予防及び／又は改善剤
PL3626258T3 (pl) 2010-06-25 2022-01-17 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
US20140066439A1 (en) * 2010-11-10 2014-03-06 Katholieke Universiteit Leuen, K.U.Leuven R&D Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
JP6175431B2 (ja) 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
US20220288096A1 (en) 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
SG11201509030TA (en) 2013-05-07 2015-11-27 Bio Blast Pharma Ltd Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
US10906981B2 (en) 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
EP3220906B1 (en) 2014-11-19 2022-03-02 Rush University Medical Center Compositions and methods for treating lysosomal disorders
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof
WO2017136533A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses
JP7302871B2 (ja) 2016-04-21 2023-07-04 ベイラー カレッジ オブ メディスン リソソーム蓄積障害およびリソソーム機能不全によって特徴付けられる障害を治療するための組成物および方法
IL291799A (en) 2019-10-01 2022-06-01 Seelos Therapeutics Inc Trehalose formulations and uses thereof

Similar Documents

Publication Publication Date Title
JP2016518403A5 (enExample)
US12343342B2 (en) Methods for treating soft tissue sarcoma
US20220112277A1 (en) Anti-CGRP Antibody Formulation
KR101907411B1 (ko) 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
Malär et al. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
US9913853B2 (en) Stabilized liquid fosaprepitant formulations
EP2938325B1 (en) Diclofenac composition
CN101677987A (zh) 不含吐温80的多西他赛的增溶制剂
CN113797343A (zh) 使用辅酶q10联合疗法治疗癌症
KR20180008305A (ko) 사이클로 히스티딘-프롤린을 유효성분으로 포함하는 세포 보호용 조성물
EP3285758B1 (en) Co-crystal composition and its pharmaceutical use
JP2016516773A5 (enExample)
EP3528786B1 (en) Liquid formulations of daptomycin
KR20220161403A (ko) 아리피프라졸 주사가능한 제제의 투여 방법
CN110035740A (zh) 稳定的水性辣椒素可注射制剂及其医学用途
JP2019530648A5 (enExample)
CN107810000A (zh) 来氟米林的可注射药物组合物
EP3881856A1 (en) Pharmaceutical composition for treating aplastic anemia
EP2974723A1 (en) Application of phthalide compound
US20220211663A1 (en) Nano co-delivery of quercetin and alantolactone promotes anti-tumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer
CN102481342A (zh) 使用促皮质素释放因子治疗癌症的方法
JP2016537428A (ja) エフェドラ・アラタ抽出物及びその使用方法
EP4076417A1 (en) Caffeine citrate formulations
EP3632446B3 (en) Immunoablative therapies
Kumar et al. Parenteral Suspensions: Stability Enhancing Liquid Dosage Forms